AFFYMAX INC (AFFY)

Overview Price 11.01 Price Change Today +$0.36 (+3.38%) P&P rating Zacks Rank 5 - STRONG SELL Open Price $10.64 Previous Close $10.66 Daily Range $10.59 - $11.13 52-Week Range $3.93 - $11.13 Volume 1,597,071 AFFYMAX INC., is a biopharmaceutical company that is developing a pipeline of synthetic peptide-based drug candidates against clinically validated targets for the treatment of kidney diseases and cancer. Affymax's objective is to discover, develop and commercialize novel therapeutics addressing large unmet medical needs. A collaboration of several venture firms created Affymax as an independent company a spin-out from GlaxoSmithKline. Affymax has leveraged its foundation to become a developer of peptide drugs. Their lead product,Hematide, is a synthetic peptide-based erythropoiesis-stimulating agent in clinical development for the treatment of anemia. Hematide is currently entering Phase THREE clinical trials for the treatment of anemia associated with chronic renal failure and is in Phase TWO clinical trials for the treatment of anemia in cancer patients. Other Resources for AFFY Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary Zacks Blog: Company News for December 6, 2011 December 6, 2011 Zacks Blog: Zacks #5 Rank Additions for Friday November 11, 2011 AFFYMAX INC., is a biopharmaceutical company that is developing a pipeline of synthetic peptide-based drug candidates against clinically validated targets for the treatment of kidney diseases and cancer. Affymax's objective is to discover, develop and commercialize novel therapeutics addressing large unmet medical needs. A collaboration of several venture firms created Affymax as an independent company a spin-out from GlaxoSmithKline. Affymax has leveraged its foundation to become a developer of peptide drugs.Their lead product,Hematide, is a synthetic peptide-based erythropoiesis-stimulating agent in clinical development for the treatment of anemia. Hematide is currently entering Phase THREE clinical trials for the treatment of anemia associated with chronic renal failure and is in Phase TWO clinical trials for the treatment of anemia in cancer patients.   Brokerage Analyst Recommendations 6 Brokerage Firms Covering AFFY   Strong Buy 5 Buy 0 Hold 1 Sell 0 Strong Sell 0 Average Broker Recommendation (ABR): 1.33   AFFY Ratings: BUY  SELL  HOLD AFFY Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 2 Buy 0 Sell   Top Buy Analysis BUY: AFFY Company: AFFYMAX INC Points: 50.16 Start Price: $7.09 Start Date: 01/12/2012 5:57 PM CCZacks P&P Score: 99.04 Recs: Received strong recommendation for FDA approval end of 2011. Approval likely to be obtained in March 2012. Comments: 0 | Comment More Recent Analysis Top Sell Analysis No Sell Analysis. Be the First. More Recent Analysis

Blog Posts

User	User Score	Date	Title	Comments	Last Comment
rjm77me	99.92	12/07/11	Affymax Inc. (AFFY)	1	12/07/11
rjm77me	99.92	02/03/11	Will you be happy to bless your daughters wedding to Casino High Roller or steady eddy Accountant	3	02/03/11
rjm77me	99.92	02/01/11	GIS as value play	3	02/04/11
ThisColoradoKid	99.65	01/20/11	1-20-11: Pullback	0
ThisColoradoKid	99.65	12/04/10	12-4: Adding a number of stocks in a trading range	0

Commentary

BUY: AFFYMAX INC (AFFY) Start Price: $7.09 Points: +50.16 Created: 01/12/2012 Received strong recommendation for FDA approval end of 2011. Approval likely to be obtained in March 2012. Comments: 0 | Comment CCZacks Recs:

BUY: AFFYMAX INC (AFFY) Start Price: $6.40 Points: +65.37 Created: 06/12/2011 Comments: 0 | Comment dmb Recs:

Picks

Username	P&P Score	Call	Time Frame	Start Date	Start Price	Today (change)	Stock Gain	S&P Gain	Points	Analysis
CCZacks	99.04	BUY	One to Three Months	01/12/2012	$7.09	$10.98 (+4.27%)	+54.87%	+4.70%	+50.16	view close
dmb	0.28	BUY	One to Three Months	06/12/2011	$6.40	$10.98 (+4.27%)	+71.56%	+6.20%	+65.37